Over 60 experts, scholars, and heads of regulatory agencies from the biomedical industry attended the First International MAH Cooperation and Innovation Summit launched in Qiantang District of Hangzhou recently.
The summit was sponsored by the Pharmaceutical Marketing Authorization Holder (MAH) Conversion Platform of Zhejiang Province which has recruited 1,856 member enterprises at present. The platform has helped member enterprises meet their needs for more than 900 times and has established the first demonstrative industrial park for MAH license conversion.
The First International MAH Cooperation and Innovation Summit focuses on MAH system, and centers on MAH regulation and cooperation on drug approval under MAH system to explore how enterprises can take the lead in the global trend of pharmaceutical innovation and development under MAH system. The summit also presents opinions and suggestions on how to develop MAH system in China.